Business, energy, technology, markets and global industry news from Business News Today

Nasdaq

PharmaDeviceNews Nasdaq
A laboratory scene reflecting Acurx Pharmaceuticals’ ibezapolstat development as FDA guidance opens a potential single Phase 3 pathway for treating Clostridioides difficile infection and reducing recurrence. Representative image.
Pharma & Biotech

What FDA’s latest ibezapolstat guidance means for Acurx and the IBZ-ASPIRE trial

FDA feedback may let Acurx use one Phase 3 ibezapolstat trial for C. difficile treatment and recurrence, but evidence and funding remain decisive.

Read More
Galmed Pharmaceuticals is developing an oral dispersible film formulation of Aramchol for Parkinson’s disease, aiming to combine brain penetration with easier long-term dosing, although clinical efficacy in patients remains unproven. Representative image.
Pharma & Biotech

Can Galmed’s dissolving Aramchol film turn a former liver drug into a Parkinson’s contender?

Galmed’s Aramchol film may simplify Parkinson’s dosing, but clinical proof and regulatory clearance remain ahead. See what matters next.

Read More
Novanta Inc.’s $1.2 billion acquisition of Riverpoint Medical expands its position in surgical consumables, implantable materials and minimally invasive medical device manufacturing. Representative image.
Medical Devices & Diagnostics

Novanta just made a $1.2bn surgical consumables bet. Can Riverpoint justify the price?

Novanta completes Riverpoint Medical acquisition, expanding surgical consumables and recurring revenue. See what integration and returns must deliver.

Read More
A molecular illustration of antibody activity highlights argenx SE’s $2.2 billion acquisition of Forte Biosciences and the addition of investigational anti-CD122 antibody FB102 to its immunology pipeline. Representative image.
Pharma & Biotech

argenx Forte Biosciences acquisition: What the $2.2bn FB102 deal means for immunology

argenx is buying Forte Biosciences for $2.2bn to secure FB102. See why early vitiligo and celiac data make Phase 2 execution decisive.

Read More
Representative image: Apnimed, Inc. has filed for a Nasdaq IPO as investors weigh the commercial potential and FDA approval prospects of AD109, its once-nightly oral treatment for obstructive sleep apnea.
Pharma & Biotech

Apnimed files for Nasdaq IPO as oral sleep apnea drug AD109 nears FDA review

Apnimed, Inc. has filed for an initial public offering in the United States as it prepares for a potentially decisive regulatory year for AD109, its once-nightly oral treatment for obstructive sleep apnea. The Cambridge, Massachusetts-based pharmaceutical company plans to list on the Nasdaq Global Market under the ticker APMD, although the number of shares, proposed

Read More
Pharma & Biotech

Compass Pathways has stronger COMP360 data, but can psilocybin treatment scale?

Find out how Compass Pathways’ COMP360 Phase 3 data could shape regulated psilocybin treatment for depression.

Read More
Pharma & Biotech

UroGen Pharma has FDA clearance for UGN-501, but can an oncolytic virus work in bladder cancer?

Find out how UroGen Pharma’s UGN-501 could test oncolytic virus therapy for recurrent non-muscle invasive bladder cancer.

Read More
Pharma & Biotech

Gain Therapeutics has FDA clearance for GT-02287, but can biomarkers become real benefit?

Find out how Gain Therapeutics’ GT-02287 could test GCase restoration as a disease-modifying strategy for Parkinson’s disease.

Read More
Medical Devices & Diagnostics

QT Imaging passed its first FDA inspection cleanly, but can adoption follow?

Find out how QT Imaging’s clean FDA inspection could support Breast Acoustic CT scale-up and breast imaging adoption.

Read More
Representative image of oncology drug discovery as Parabilis Medicines’ IPO surge puts Helicon peptides, zolucatetide, desmoid tumors, and Wnt-driven cancer treatment under sharper focus.
Pharma & Biotech

Parabilis Medicines IPO boom raises the bar for zolucatetide clinical execution

Find out how Parabilis Medicines’ IPO surge could reshape investor appetite for Helicon peptides and Wnt-driven oncology drugs.

Read More